Loading clinical trials...
Loading clinical trials...
An Open-Label, Multicenter Study to Evaluate the Safety and Effectiveness of Intravenous CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus
Conditions
Interventions
CR845 0.5 mcg/kg
Locations
47
United States
Cara Therapeutics Study Site
Escondido, California, United States
Cara Therapeutics Study Site
Riverside, California, United States
Cara Therapeutics Study Site
San Diego, California, United States
Cara Therapeutics Study Site
Victorville, California, United States
Cara Therapeutics Study Site
Denver, Colorado, United States
Cara Therapeutics Study Site
Middlebury, Connecticut, United States
Start Date
May 6, 2019
Primary Completion Date
February 26, 2020
Completion Date
March 6, 2020
Last Updated
October 15, 2021
NCT02143648
NCT05575193
NCT04470154
NCT03422653
NCT01660243
NCT00494975
Lead Sponsor
Cara Therapeutics, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions